CDC7 inhibition plus gemcitabine in preclinical cholangiocarcinoma models
In preclinical cholangiocarcinoma models, the CDC7 inhibitor XL413 re-sensitized gemcitabine-resistant tumors; the combination activated a ROS–DNA damage–senescence cascade. This is laboratory evidence, not proof of benefit in patients. [1]
Automatic summary · not editorially reviewed
The key findings
In 16 tumor/non-tumor tissue pairs, disturbed cell cycle regulation was linked to chemoresistance and poor prognosis. [1]
The CDC7 inhibitor XL413 re-sensitized gemcitabine-resistant tumors in multiple preclinical cholangiocarcinoma models. [1]
In cholangiocarcinoma cells, CDC7 inhibitor plus gemcitabine synergistically induced cellular senescence. [1]
The source at a glance
- Study type / format
- Preclinical laboratory study (tissue analysis and cell/model experiments); abstract only.
- Population / context
- 16 pairs of human cholangiocarcinoma and adjacent non-tumor tissue, plus preclinical cholangiocarcinoma models and cells.
- Summary based on
- Study abstract
- Original publication
- October 20, 2026
Chemoresistance in advanced cholangiocarcinoma
Advanced-stage cholangiocarcinoma often becomes resistant to chemotherapy, and the authors describe an urgent need for new treatment strategies. They analyzed 16 pairs of tumor and adjacent non-tumor tissue and report that disturbed cell cycle regulation is a hallmark of this cancer, closely linked to chemoresistance and poor prognosis. On that basis they propose targeting abnormal cell cycle regulation as a way to improve treatment outcomes.
Supporting source [1]
XL413 tested in gemcitabine-resistant preclinical models
The researchers identify the CDC7 inhibitor XL413 as an agent that can re-sensitize gemcitabine-resistant tumors. This was shown across multiple preclinical models of cholangiocarcinoma, not in patients. Mechanistic analyses, including transcriptomic profiling, examined which pathways the combination therapy activates.
Supporting source [1]
Senescence cascade seen in cells, not patient outcomes
According to the abstract, the combination therapy activates senescence-associated pathways, and the effect is described as mediated via a ROS–DNA damage–senescence cascade. In cholangiocarcinoma cells, co-treatment with a CDC7 inhibitor and gemcitabine produced a synergistic induction of cellular senescence. The authors call this robust preclinical evidence for combining gemcitabine with CDC7 inhibitors. Because this is an abstract of laboratory work, it does not show that patients live longer or respond better; the full text was not reviewed.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. All findings come from tissue samples and preclinical models, not from patients. No human efficacy, survival or safety data are reported here.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Xiao R, Hong JH, Wang P, Zhong Y, Ye Z, Hao Z, Gao J, Jiang Y, Peng Y, Chen S, Yin J, Liu L, Xiong Q, Zhang Y, Li M, Chen J, Tan J. · europepmc.org · October 20, 2026